C ombination therapy with anti-tumor necrosis factor-alpha medications (anti-TNFs) and thiopurines is recommended in moderate-to-severe Crohn's disease (CD). [1] [2] [3] [4] Concerns remain about the safety of this combination. The 2 most feared complications are infection and malignancy. There are conflicting data on whether anti-TNFs, and combination therapy in particular, increase the risk of serious infections such as pneumonia. 5, 6 An increased risk of malignancy, particularly lymphoma and non-melanoma skin cancer, has been demonstrated in several observational cohorts. [7] [8] [9] The existing evidence implicates thiopurines as the principal cause of lymphoma, with a possible synergistic effect when combined with anti-TNFs. 8, 10 Thiopurines also appear to be the dominant risk factor for hepatosplenic T-cell lymphoma (HSTCL), a rare but fatal lymphoma affecting young males. 11 Therefore, discerning whether combination therapy offers an overall benefit relative to anti-TNF monotherapy is complex.
The incidence of non-Hodgkin's lymphoma (NHL) and surgical and infectious complications with combination therapy increases with age. 12, 13 Furthermore, the expected benefit of azathioprine monotherapy decreases in older populations as a consequence of increasing lymphoma risk. 14 In this study we explored the relationship between age-specific risks and the expected net benefit of combination therapy compared with infliximab monotherapy. We hypothesized that for certain individuals, age-specific risks of lymphoma and infection with combination therapy outweigh the potential benefit, mandating personalized therapy incorporating this riskbenefit balance.
Methods
We constructed a Markov model to assess agespecific risks of combination therapy with an anti-TNF and thiopurine compared with anti-TNF monotherapy. The base case was a 35-year-old man with moderate-tosevere CD, comparable to participants in the Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease (SONIC) trial, 1 initiating either combination therapy or infliximab monotherapy. It was assumed that surgery was the least desired option. The time horizon for the primary analysis was 1 year, with a 1-month cycle length.
Combination therapy or monotherapy could initially result in remission, clinical response, or non-response ( Figure 1) . With response or remission, individuals could lose response, have a complication requiring cessation of the medication, experience a serious infectious complication requiring temporary withholding of medication for 1 cycle, develop lymphoma, or remain in their current state. Those without response and those that flared were transitioned to a second anti-TNF (adalimumab), with similar health states as with infliximab. All patients in the base model were continuously exposed to the age-specific probability of death of a male patient with CD, which was calculated by using the baseline rate of Figure 1 . Model structure for combination therapy and monotherapy. This is the structure of the model for the combination therapy arm. The monotherapy arm is identical, without inclusion of azathioprine. AE, adverse event; Infx, infliximab; LOR, loss of response.
death in U.S. census data and a hazard ratio of 2.44 for those with CD on immunosuppressive therapy. 15, 16 Individuals entering a lymphoma state remained there and were exposed to both age-specific and sexspecific all-cause and lymphoma-specific mortality. Lymphoma-specific mortality was derived from Surveillance, Epidemiology, and End Results (SEER) age-specific and sex-specific data. 17, 18 It was assumed that all patients received standard of care chemotherapy for lymphoma.
Patients undergoing surgery were exposed to an increased risk of perioperative mortality for 1 cycle. Then they entered a postsurgical remission state for the remainder of the study period, without exposure to medications and their risks.
Transition Probabilities and Outcome Estimates
Transition probabilities were derived from relevant clinical trials (Table 1 , Supplementary Methods). The transition probabilities related to infliximab induction, maintenance, and complications were derived from the SONIC trial. 1 The Gauging Adalimumab Efficacy in Infliximab Non-responders (GAIN) study was used to inform initial remission and response rates for adalimumab. 19 Relapse, infection, and adverse event rates for adalimumab were derived from the Crohn's Trial of the Fully Human Antibody Adalimumab for Remission Maintenance (CHARM) study. Because there was no clear difference between combination therapy and monotherapy with adalimumab for relapse in CHARM, which has been confirmed in 2 recent meta-analyses of adalimumab combination and monotherapy, these transition probabilities were considered equivalent and were derived from those previously exposed to infliximab in CHARM. [20] [21] [22] It was assumed that the hazard ratios (HRs) for azathioprine and infliximab were independent of each other. The baseline HR for azathioprine was determined to be 5.28 from the Cancers Et Surrisque Associé aux Maladies Inflammatoires Intestinales En France (CESAME) cohort and was treated as a continuous risk. 8 The baseline HR for infliximab was 1.0, which was based on the nonsignificant standardized incidence ratios (SIRs) in CESAME and the TREAT registry. 23 These hazards were applied to the age-specific rate of lymphoma as determined by SEER. 17 Quality-adjusted life year (QALY) estimates were derived from previously published estimates and expert opinion (Supplementary Methods).
14,18,24 QALY estimates were assumed to be constant over all age ranges (Table 1) .
Statistical Analysis
Analyses were conducted from age 25 to 75 years by using TreeAge Pro 2013 (TreeAge Software, Inc, Williamstown, MA). Means and standard deviations for QALY estimates were derived from first-order Monte Carlo simulations (FOMCS) by using 50,000 subjects. Probabilistic analyses were performed by using distributions derived from clinical trials for all transition probabilities and QALY estimates (Supplementary Methods). 25 To simulate outcomes at the end of 1 year, Markov cohort analysis was performed by using a cohort of 1,000,000 patients for all age ranges.
Sensitivity Analyses
One-way sensitivity analyses were performed for all transition probabilities, HRs, and rewards. Alternative model designs were also examined by assessing the impact of (1) using a second anti-TNF by conducting an analysis allowing only infliximab, (2) life years lost because of death during the first year of therapy by modifying the final reward, (3) increased risk of perioperative mortality in those older than 65 years of age, (4) increasing age-specific risks of serious infection and infection-related mortality for those older than 65 years of age, (5) lymphoma-specific life years lost for duration of therapy up to 9 years, (6) a gradual increase rather than instantaneous risk of lymphoma with azathioprine, and (7) including an additional risk of HSTCL for 25-year-olds treated with combination therapy (Supplementary Methods).
Results
Combination therapy with infliximab and azathioprine was the preferred option in the base model (expected QALYs, 0.7522 versus 0.7426; incremental effectiveness [IE], 0.0096). This benefit was also appreciated in first-order Monte Carlo analysis (IE, 0.0097) and probabilistic analyses (mean expected QALYs, 0.7521 versus 0.7426; IE, 0.0095; 95% confidence interval, À0.0076 to 0.0268). In 50,000 iterations of the probabilistic model, combination therapy was the preferred strategy 86.1% of the time. In Markov cohort analysis, combination therapy resulted in a greater number of patients in remission (22.9% versus 20.7%) and with response (26.8% versus 22.5%), fewer in postoperative remission (25.5% versus 30.1%), and fewer with active disease (24.4% versus 26.3%) at 1 year (Supplementary Figure 1) . Mortality rates were similar between groups, with 19 fewer deaths per million individuals at 1 year in combination therapy (Table 2) .
Combination therapy remained the preferred therapy throughout the life span ( Figure 2 ). The increase in rates of lymphoma with age, particularly in the combination therapy arm (Supplementary Figure 2) , resulted in increased mortality in the combination therapy arm compared with monotherapy for those older than 55. Per 1,000,000 patients treated, there were 29 more deaths with combination therapy at age 55, 147 at age 65, and 455 at age 75 (Table 2) . 
Alternative Model Structures
Combination therapy yielded greater QALYs in alternative models that (1) Assessing the impact of HSTCL in younger male patients, combination therapy remained the preferred strategy (expected value, 0.7524 versus 0.7428; IE, 0.0096). However, in our Markov cohort analysis, there were 37 excess deaths with combination therapy because of 67 additional HSTCL-related deaths. When accounting for life years lost because of HSTCL, the margin of benefit was reduced compared with the base model (IE, 0.0075). Monotherapy became the preferred strategy if the incidence of HSTCL was greater than 36.0 per 100,000 or 3.2-fold greater than the baseline estimate.
In one-way sensitivity analysis of HR for azathioprine-related lymphoma accounting for life years lost because of death, monotherapy became the preferred strategy in 65-year-olds if HR for combination therapy was >13.6 and in 75-year-olds if HR was >8.1 ( Figure 3) .
When extending the time horizon, combination therapy remained the preferred strategy for all ages for up to 3 years of therapy ( Figure 4 , Supplementary Table 1) . Monotherapy was preferred in patients age 75 with more than 5 years of therapy and in those age 55 or older with more than 9 years of therapy.
Sensitivity Analyses
The model was not sensitive to changes in transition probabilities across a range from 50% lower than to 50% greater than the base value for adverse event, response, relapse, mortality, or infection rates for combination or monotherapy. However, if the probability of remission with combination therapy with infliximab and azathioprine decreased to 20.8%, or 8.8% below the monotherapy remission probability, monotherapy became the preferred therapeutic option. If the remission rate with infliximab monotherapy exceeded 42.1%, monotherapy The model was robust to estimates of infection risk. The model was not sensitive to infection rates related to anti-TNFs or combination therapy when increased to up to 5 times of the base estimate, regardless of age (Supplementary Methods, Supplementary Figure 4) . In a 2-way sensitivity analysis, monotherapy became the preferred strategy when the odds of infection with combination therapy were >10Â monotherapy and the infection-specific mortality exceeded 10% (Supplementary Figure 5) .
Discussion
Concerns about age-related risks with immunomodulators and biologic therapies in inflammatory bowel disease have markedly impacted willingness to use our most effective therapies in the youngest and oldest patients. In this study, we modeled the age-specific risks and benefits associated with combination therapy for moderate-to-severe CD, demonstrating that combination therapy may yield the greatest clinical benefit for shortterm therapy in patients aged 35-65. However, the risks associated with combination therapy may outweigh the benefits for those older than 65, particularly with longer treatment periods. This appears to be driven by lymphoma-related complications as opposed to increased risks of surgical complications or infection, even though infectious complications are far more common than lymphoma. Our sensitivity analyses highlight this finding, demonstrating no change in the optimal therapy with increasing age-specific risks of infection or surgery.
We used several novel techniques in estimating the age-specific benefits and risks of combination therapy. We used age-dependent rates of NHL, infection, and surgery to better capture these risks for all individuals and assessed the impact of these rates on long-term therapy. By using these approaches, we demonstrated that monotherapy yielded greater clinical benefit in patients older than 75 when therapy exceeded 5 years and was preferred in those older than 55 years of age if therapy exceeded 9 years. This highlights the complicated risk-benefit analyses required to ascertain the preferred strategy for a given individual.
We determined thresholds for lymphoma risk that would indicate change in preferred strategy. For only 1 year of therapy, the HR of lymphoma with combination therapy would need to be greater than 8.1 for monotherapy to become the preferred strategy in those older than 75; this threshold is well within the 95% confidence interval reported in CESAME (HR, 5.28; 95% confidence interval, 2.01-13.9). 8 This model assesses the impact of HSTCL in younger male patients. We demonstrated that there was a tradeoff between the small increased risk of death from HSTCL and increased therapeutic efficacy with combination therapy. We estimated that the risk of HSTCL must exceed a threshold of 36 per 100,000 person-years of exposure to thiopurines for monotherapy to yield greater QALYs. It seems unlikely that the true incidence is this high. The annual incidence of NHL among 25-yearold American men is approximately 4 per 100,000. Therefore, the estimated annual incidence in thiopurineexposed is only 21 per 100,000 on the basis of the relative risk estimates from CESAME, well below the threshold of 36 per 100,000.
We can also use this sensitivity analysis to consider the impact of other thiopurine-related complications in young male patients. Hemophagocytic lymphohistiocytosis is a potentially fatal complication associated with primary Epstein-Barr virus (EBV) infection when taking azathioprine. CESAME reported 2 deaths from complications related to primary EBV infection in young male patients using thiopurines for an estimated incidence rate of 10 per 100,000 person-years. 8 When considering only young male patients who are EBV-seronegative, the incidence of this event may be as high as 290 per 100,000 person-years. 26 Combining the more conservative estimate of 10 per 100,000 with our estimated rate of HSTCL, the overall incidence rate of these 2 fatal complications of thiopurine therapy is 21.2 per 100,000 person-years, which is much closer to the threshold we estimated. If the true incidence of fatal primary EBV infection among EBV-seronegative patients is closer to 290 per 100,000 person-years, our model would strongly favor monotherapy in this subpopulation.
There are several important caveats to interpreting our results. The overall incremental effectiveness is Figure 4 . Impact of age with increasing time horizon. Impact of age on preferred strategy in models that account for 3, 5, 7, and 9 years of exposure, from 25 to 75 years old.
small. However, in Markov analysis, there were clear differences in favor of combination therapy, with 64,102 more individuals with clinical improvement and 62,072 fewer individuals requiring surgery, having active disease, or dying.
The key transition probabilities were derived from large clinical trials. Notably, in a recent meta-analysis comparing combination therapy and monotherapy, the pooled odds of remission at 24 weeks was 1.64, favoring combination therapy, similar to the odds ratio of 1.62 in SONIC. 27 Pooled estimates of infection and adverse events were also comparable to those in SONIC. 27 Recent meta-analyses also support our assumption of equivalent relapse rates for adalimumab combination and monotherapy. 21, 22 We did not model dose escalation or antibody measurement with loss of response. There are limited and conflicting data regarding the efficacy of this treatment strategy. 28, 29 Because our model was insensitive to relapse transition probabilities, utilization of these tests would not markedly impact our results.
We assumed that the risk of lymphoma begins immediately with azathioprine initiation. This risk may increase over time with therapy. 30 We therefore assessed models with extended time horizons and performed a sensitivity analysis increasing azathioprine-related risk of lymphoma over time. These models yielded similar results, demonstrating that for those older than 65, the risks of combination therapy beyond 6 years may outweigh the potential benefits.
Our estimated rate of HSTCL was based on limited data; if true rates are much lower, combination therapy would be the preferred strategy in younger male patients. Some reports suggest that HSTCL rarely occurs before several years of therapy with thiopurines, and we therefore may have overestimated the impact of HSTCL. We did not model the impact of discontinuing azathioprine after the first few years of therapy in models with longer time horizons. As more data become available, future models should evaluate this potential strategy. We did not model the impact of combination therapy with methotrexate in young male patients, although a recent trial failed to demonstrate a therapeutic advantage with this regimen compared with anti-TNF monotherapy. 31 Last, we focused on the risk of lymphoma as opposed to other neoplasms. Our model does not take into account increased rates of certain skin cancers with these medications or the possible increased risk of other tumors recently appreciated with combination therapy.
9,32,33 However, we did account for increasing age-related risks of infection and surgery and demonstrated that they did not impact the optimal strategy. In summary, this study assesses the impact of age-specific risks on the decision to use combination therapy versus monotherapy for patients with moderateto-severe CD. In our model, increased lymphoma, infection, and surgery risks do not outweigh the greater efficacy of combination therapy for those aged 35-65 when considering therapy for up to 3 years. However, the risk of lymphoma may outweigh the benefits of combination therapy for those older than 65, particularly with long-term therapy. These data highlight the need to further examine de-escalation strategies with long-term remission. Our model also suggests that combination therapy in young adult men may be the preferred strategy, providing greater QALYs, albeit at the cost of an increased risk of HSTCL-related deaths. Our data also support a potential strategy of screening for EBV in those younger than 25 before embarking on combination therapy to prevent primary EBV infection-related complications. This may represent a greater risk than HSTCL in this population. 26 These data help to better inform conversations with individual patients of all ages.
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Supplementary Methods

Transition Probabilities and Qualityadjusted Life Year Estimate Sources
Transition probabilities for both combination therapy with infliximab and azathioprine and infliximab monotherapy were derived from relevant clinical trials. The transition probabilities for initial response and remission rates, rates of relapse, adverse events, and infection were derived from the SONIC trial. 1 All patients who failed initial therapy received adalimumab, either in combination with azathioprine or as monotherapy as dictated by their initial treatment selection. The GAIN study was used to inform initial remission rates with adalimumab, stratified by concomitant immunomodulator use. 2 Because response rates were not stratified in this study, the same differential rate between those on combination therapy or monotherapy appreciated for remission was applied to the response rates. Relapse rates stratified by concurrent immunomodulator use were derived by using CHARM. 3 Baseline estimates for loss of remission and response were similar for those on combination therapy or monotherapy. We therefore chose the more conservative estimate that was based on prior therapy with infliximab and applied the equivalent rate to both combination and monotherapy arms for loss of remission and loss of response. A recent meta-analysis presented at ECCO in Copenhagen in 2014 by Koplyov et al 4 supports the use of equivalent relapse rates for combination therapy and monotherapy with adalimumab. Analysis of 6 trials for maintenance of remission and 3 trials for maintenance of response demonstrated no significant benefit for combination therapy with adalimumab (remission: odds ratio, 1 5 For both combination therapy and monotherapy, patients could develop a serious adverse event requiring drug cessation. Alternatively, they could develop an infectious complication, resulting in 1-month cessation of therapy and subsequent resumption of treatment. Rates of these complications were derived from SONIC when subjects were on infliximab. 1 Similarly, adalimumab therapy could result in both of these complications as well, and rates were derived from the CHARM trial of maintenance therapy with adalimumab. 2, 3 This study did not stratify these rates on the basis of concomitant immunosuppression but did state that rates were similar between those receiving immunomodulators and those who did not. Therefore, we used the same rates of adverse events for both arms for adalimumab use and performed an additional sensitivity analysis to assess higher rates in those with combination therapy.
For the risk of lymphoma, it was assumed that HRs for azathioprine and infliximab were independent of each other. The baseline HR for infliximab was set to 1.0, which was based on both CESAME, which demonstrated a nonsignificant SIR, and data from the TREAT registry. 6 The baseline HR for thiopurine use was derived from CESAME and was set at 5.28. 7 Of import, CESAME assumed a constant continuous risk of lymphoma related to thiopurine exposure. The increased risk observed in CESAME was converted to an instantaneous probability and applied to the age-specific rate of lymphoma for the base case, as determined by the SEER database. 8 Those individuals on combination therapy are exposed to both HR of infliximab for lymphoma and HR of the thiopurine, with an assumed multiplicative interaction. Mortality rates for each arm were assumed to be similar to those seen within the general population based on recently published data. Age-specific and sex-specific mortality rates were derived from SEER as well. 8, 9 Overall agespecific survival rate tables from SEER were used to generate these mortality rates, with the model referencing the age of the individual at the time of diagnosis and then the cycle since diagnosis to determine the transition probability, adjusting this value on the basis of time in the lymphoma node of the model (Supplementary Table 2 ). Because some patients may be diagnosed with more advanced forms of NHL, we performed a sensitivity analysis of this mortality rate over a AE50% range. The model was insensitive to these values.
QALYs were used for rewards assigned in transition from state to state (Table 1) . QALY estimates for severe CD, medical remission, infection, and adverse events were assigned by using previously published estimates.
10,11 QALY estimates for mild CD were assumed to be at the mid-point of severe CD and CD in remission. These QALY estimates were assumed to be constant over all age ranges. With regards to lymphoma, the QALY estimate in the primary analysis was consistent with previously used estimates in models of CD. 10 It is important to note that this value is not adjusted for active CD, which is based on data suggesting that patients with CD who are undergoing chemotherapy are typically in remission because of the profound immunosuppression. 12 In addition, for the iterations of the model using an extended time horizon, we assumed patients would enter an active CD state and remain there after treatment for lymphoma, assumed to be 4 years in length. However, because these estimates are based on a small cohort study and assumptions about outcomes of therapy, we performed a sensitivity analysis of the point estimate of 0.47 by using a range from 0.20 to 0.80. The model was not sensitive to these estimates.
Alternative Model Structures
Impact of allowing sequential anti-tumor necrosis factor use. We examined a version of the model without therapy crossover, where after failing initial combination or monotherapy, patients went to surgery. Because patients in this study are assumed to have moderate-tosevere CD, those who failed initial combination therapy or infliximab monotherapy then entered a state of severe CD, with a continuous risk of requiring surgical intervention until the 1-year time horizon was reached. As with the base model, expected values and incremental effectiveness were calculated for this model.
Accounting for future life years lost because of mortality and chronic disease states. We also performed an iteration of the model to account for future life years potentially lost because of mortality during the model time horizon. In one analysis, a final reward was applied equivalent to the remaining life expectancy according to U.S. census data.
Risk of surgical events in the elderly. We assessed the potential impact of increased risk of surgery in the elderly by inserting a modifier of the relative risk of surgical complications or mortality in those who were older than 65 years. This relative increased risk was assumed to be a 2-fold increase. We performed an additional one-way sensitivity analysis on this value of increased relative risk, increasing it to a 5-fold increased risk.
Risk of infection with anti-tumor necrosis factors and azathioprine combination therapy. Because of the limited data on the risk of infection and infection-related mortality with both anti-TNFs and in particular combination therapy, we conducted 3 additional sensitivity analyses examining these specific risks and then repeated these analyses throughout the life span. In the initial analysis, we performed a wider sensitivity analysis of anti-TNF infectious risks. We demonstrated in this model that with an increased odds ratio of infection from 1 to 5 over the rates used in this study, there is no change in preferred strategy in the base model (Supplementary Figure 5A) . We repeated this analysis in 10-year increments from 25 to 75 years of age, with no change in results (data not shown). In the SONIC trial, serious infections were less common in the combination therapy group. Therefore, another sensitivity analysis only increased the risk of infection with combination therapy. Although there was a modest reduction in QALYs with increased risk of infection (odds ratio range, 1-5) for azathioprine, the preferred strategy remained combination therapy (Supplementary Figure 5B) . This again remained true if this increased risk of infection with combination therapy is applied in those from age 25 to 75 (Supplementary Figure 4) . We also performed a 2-way sensitivity analysis of the risk of infection with combination therapy, as above, with the risk of death related to infection. Monotherapy became the preferred strategy only when the odds of infection were >10Â monotherapy and the risk of death related to that infection exceeded 10% (Supplementary Figure 5C) .
Lymphoma-related alternative model structures. We performed several analyses examining our assumptions for QALYs and risk of lymphoma. With regards to our QALY assessment for active lymphoma, recent models for NHL have used a QALY estimate of 0.70 for Rituximab-Cyclophosphamideþ Hydroxydaunorubicinþ OncovinþPrednisone (R-CHOP), a common chemotherapeutic regimen for chemotherapy. 13 Therefore, we performed a one-way sensitivity analysis on the QALY estimate for lymphoma.
We also assessed the instantaneous risk of lymphoma used in our model. In our primary models, we assumed an instantaneous, constant hazard of lymphoma when on azathioprine. It is possible that this risk is not instantaneous, with an initial lower risk that increases to HR described in CESAME over time. Furthermore, it is possible that the cumulative effects of this risk over time may not be properly assessed in our base model with a 1-year time horizon. We attempted to assess this via 2 alternative models. For these models, the time horizon was extended to 3 years, 5 years, 7 years, and 9 years to assess the long-term impact of these medications.
In the first iteration, we assessed the impact of the time horizon on rates of lymphoma and option preference. We extended the time horizon to 3 years, 5 years, 7 years, or 9 years. Rates of loss of response, risks of side effects, and risks of lymphoma and lymphoma-related mortality were held constant throughout the time assessed within the model and equivalent to those used in the base model. As such, there was a continuous attrition from medical therapy as a result of all causes in the base model. As with the base model and prior iteration assessing the long-term impact of lymphoma risks, we calculated age-specific continuous risks of lymphoma throughout the time period. QALY estimates calculated in this model accounted only for the time horizon of the model without an additional final reward reflecting remaining life expectancy.
In the second iteration, we also modified the risk of lymphoma over time to assess the impact of a delayed onset of risk of lymphoma in those who were maintained on their therapy. For this model, the initial year of therapy was structured as in the base model for all age ranges for therapy efficacy and risks of flare, infection, and non-lymphoma adverse events. After 1 year, it was then assumed patients who were on medication remained stable in their remission or response state until 3, 5, 7, or 9 years. During the first 2 years of the model, patients were exposed to a reduced hazard of lymphoma that increased linearly in the combination therapy arm until reaching the value of 5.28 appreciated in CESAME by using the following formula:
Current cycle HR aza ¼ ððHR aza À 1ÞÃðcurrent_cycle=24ÞÞ þ 1Þ until current_cycle ! 24
This was then applied throughout the life span at the time horizons noted above for comparison to the other models.
For both of these model iterations, the time horizon was adjusted as noted above, and the model was run from ages 25 to 75 as with the base model. Expected values were calculated for each time horizon group and age subgroup for each treatment arm. IE was then calculated by comparing combination therapy with anti-TNF monotherapy. Markov cohorts were estimated for each time horizon as well to assess the number of deaths and number of cases of lymphoma for combination therapy and monotherapy. IE, mortality, and lymphoma estimates are presented in Supplementary Table 1 .
Of note, neither of these models applied an extra reward to the final health state equivalent to the remaining life expectancy. As such, these models undervalue the reduction in lifetime QALYs resulting from premature death. Despite this, with longer duration, monotherapy becomes the preferred strategy in older patients (age 75) with as little as 5 years of therapy and in those aged 55 or older with up to 9 years of therapy (Supplementary Table 1) .
Last, in our base model, infliximab was assigned HR of 1.0 for lymphoma. It is possible that this is an underestimate of the risk of lymphoma attributable to infliximab. We therefore performed a sensitivity analysis looking at this specific value, and the model was not sensitive to this estimate (Supplementary Figure 3) . We also assessed the impact of varying HRs on overall rates of lymphoma within the model by using the baseline risk (1.0), 2.0, and 3.0 to determine how that would change overall lymphoma rates in Markov cohort analysis (Supplementary Table 3 ).
Risk of Hepatosplenic T-cell Lymphoma in Young Male Patients
We also wished to assess the impact of the increased risk of HSTCL in younger male patients. To assess the impact of this rare but usually fatal disease, we created an iteration of the model for 25-year-old men where this was a potential complication in combination therapy alone. The risk of HSTCL was derived from a pooled analysis of 2 large observational studies. 7, 14 In one study that used the Kaiser Permanente Northern California data set, Herrinton et al 14 identified 1 case of HSTCL within 3652 person-years of exposure. In the CESAME cohort, there were no cases of HSTCL among 16,659 person-years of current thiopurine exposure. Therefore, there was 1 case among 20,311 individuals actively being treated with a thiopurine; assuming 44% of exposure was among male patients, we estimated the incidence of HSTCL among thiopurine-exposed male patient to be 11.2/100,000 person-years. 7, 14 This was included in our model as an instantaneous probability. It is important to note that this may overestimate this risk, because smaller studies have noted that the reported cases of HSTCL all occur after several years of exposure. 15 We then assessed what incidence rate of HSTCL would be required for monotherapy to be the preferred strategy and performed a Markov cohort analysis to assess the increase in mortality directly attributable to HSTCL.
Probabilistic Sensitivity Analyses
For the primary calculation of QALYs, as well as FOMCS, deterministic transition probabilities and QALYrelated rewards were used. For second-order Monte Carlo simulation, probabilistic distributions were generated for all transition probabilities and QALY distributions. For transition probabilities involving 2 potential outcomes (eg, survival of infection), beta distributions were generated by using available study data. For transition probabilities involving more than 2 potential outcomes, Dirichlet distributions were created by using available clinical data from which the original deterministic transition probabilities were derived. Dirichlet distributions are considered to be the multivariate equivalent of a beta distribution. 16 For QALY estimates, normal distributions were applied.
Several outcomes modeled in our study are sufficiently rare events (ie, death and lymphoma) that they were not observed in randomized controlled trials. Because of this, the probability estimate for these events when using a Dirichlet distribution derived directly from the literature would be 0. To assess the impact of these non-events, we created 2 sets of distributions. In the first set, the exact populations derived from the literature were used, including their 0 cells. In the second set, we also included the assumed probabilities as estimated in the deterministic analysis, as described in previous work by our group. 17 In this method, non-whole numbers were used that were based on documented rates of rare events in larger populations, multiplied against the total cohort size. This value was then used as the value for the 0 cell, and this value was subtracted from the largest cell in the distribution. These 2 methods were performed and compared to assess for changes in the standard errors for QALY point estimates and yielded similar results. Because separate distribution sets were used for the combination and monotherapy arms, we did not assess for the potential impact of reduced standard errors that result from sampling from the same set of distributions in each decision option of the tree.
